Achieving and maintaining long-term optimal improvements in patient-reported symptoms, signs, and quality of life among patients with moderate-to-severe psoriasis treated with guselkumab: 5-year data from VOYAGE 1

被引：0
|
作者：
Griffiths, Christopher E. M. [1 ]
Blauvelt, Andrew [2 ]
Han, Chenglong [3 ]
Fernandez-Penas, Pablo [4 ,5 ]
Adam, David N. [6 ,7 ]
Philipp, Sandra [8 ]
Song, Michael [9 ]
Miller, Megan [9 ]
You, Yin [9 ]
Langley, Richard G. [10 ]
机构：
[1] Univ Manchester, Salford Royal NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Dermatol Ctr, Manchester, Lancs, England
[2] Oregon Med Res Ctr, Portland, OR USA
[3] Janssen Global Serv LLC, Raritan, NJ USA
[4] Univ Sydney, Sydney, NSW, Australia
[5] Westmead Hosp, Westmead, NSW, Australia
[6] CCA Med Res Corp & Probity Med Res, Ajax, ON, Canada
[7] Prob Med Res, Waterloo, ON, Canada
[8] Charite Univ Med Berlin, Dept Dermatol, Berlin, Germany
[9] Janssen Res & Dev LLC, Raritan, NJ USA
[10] Dalhousie Univ, Halifax, NS, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27043
引用
收藏
页码：AB127 / AB127
页数：1
相关论文
共 50 条
  • [31] Early treatment targets for predicting long-term dermatology life quality index response in patients with moderate-to-severe plaque psoriasis: a post hoc analysis from a long-term clinical study
    Puig, L.
    Zhu, B.
    Burge, R.
    Shrom, D.
    Amato, D.
    Dong, Y.
    Shen, W.
    Mallbris, L.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 30 - 31
  • [32] Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
    Egeberg, Alexander
    Hawkes, Jason E.
    Somani, Najwa
    Burge, Russel
    See, Kyoungah
    Gallo, Gaia
    McKean-Matthews, Missy
    Gooderham, Melinda
    Han, George
    Armstrong, April
    DERMATOLOGY AND THERAPY, 2024, 14 (04) : 1007 - 1018
  • [33] Efficacy responses across subgroups of patients with moderate-to-severe plaque psoriasis treated with guselkumab, an anti-interleukin-23p19 monoclonal antibody: results from VOYAGE 1 through 5 years
    Thaci, D.
    Foley, P.
    Puig, L.
    Merola, J. F.
    Miller, M.
    You, Y.
    Shen, Y. -K.
    Yang, Y. -W.
    Blauvelt, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E51 - E51
  • [34] Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry
    Zhang, Junfen
    Boesjes, Celeste M.
    Loman, Laura
    Kamphuis, Esme
    Romeijn, Margreet L. E.
    Spekhorst, Lotte S.
    Haeck, Inge
    van der Gang, Lian F.
    Dekkers, Coco C.
    van der Rijst, Lisa P.
    Oosting, Albert J.
    van Lumig, Paula
    Nes, Anneke M. T. van Lynden-van
    Tupker, Ron A.
    Nijssen, Annieke
    Flinterman, Annebeth
    Politiek, Klaziena
    Touwslager, Wouter R. H.
    Christoffers, Wianda A.
    Stewart, Shiarra M.
    Kamsteeg, Marijke
    de Graaf, Marlies
    de Bruin-Weller, Marjolein S.
    Schuttelaar, Marie-Louise A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (02) : 300 - 311
  • [35] DUPILUMAB PROVIDES SUSTAINED EFFECTIVENESS IN PATIENT-REPORTED OUTCOMES AND FAVORABLE SAFETY IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: UP TO 5-YEAR RESULTS FROM THE DAILY PRACTICE BIODAY REGISTRY
    Zhang, Junfen
    Loman, Laura
    Boesjes, Celeste
    Graaf, Marlies
    Bruin-Weller, Marjolein S.
    Schut-Telaar, Marie. L. A.
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 20 - 20
  • [36] Long-term (5-year) maintenance of clinically meaningful improvement in health-related quality of life in patients with moderate to severe Crohn's disease treated with ustekinumab in the IM-UNITI long-term extension study
    Sandborn, William J.
    Ghosh, Subrata
    Han, Chenglong
    Gasink, Christopher
    Zou, Bin
    Feagan, Brian G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 108 - 109
  • [37] LONG-TERM (5-YEAR) MAINTENANCE OF CLINICALLY MEANINGFUL IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE TREATED WITH USTEKINUMAB IN THE IM-UNITI LONG-TERM EXTENSION STUDY
    Sandborn, William J.
    Ghosh, Subrata
    Han, Chenglong
    Gasink, Christopher
    Zou, Bin
    Feagan, Brian G.
    GASTROENTEROLOGY, 2021, 160 (06) : S558 - S559
  • [38] Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study
    Montorsi, F.
    Henkel, T.
    Geboers, A.
    Mirone, V.
    Arrosagaray, P.
    Morrill, B.
    Black, L.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (08) : 1042 - 1051
  • [39] Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial
    Barkin, Jack
    Roehrborn, Claus G.
    Siami, Paul
    Haillot, Olivier
    Morrill, Betsy
    Black, Libby
    Montorsi, Francesco
    BJU INTERNATIONAL, 2009, 103 (07) : 919 - 926
  • [40] Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study
    Reich, K.
    Silverberg, J. I.
    Papp, K. A.
    Deleuran, M.
    Katoh, N.
    Strober, B.
    Beck, L. A.
    de Bruin-Weller, M.
    Werfel, T.
    Zhang, F.
    Biswas, P.
    DiBonaventura, M. D.
    Chan, G.
    Farooqui, S. A.
    Kerkmann, U.
    Clibborn, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (10) : 2047 - 2055
12345